Exosome Diagnostics Inc.
Waltham, MA Doing business as Exosome Diagnostics Inc. Exosome Diagnostics, Inc. Part of Mdxhealth, Inc.
- UEI
- TCKUCULVVY39
- CAGE
- 554U8
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 621511 Medical Laboratories Primary
- Corporate family
-
-
Mdxhealth, Inc.
Parent
LQGYDJJ9K8Q6
- Exosome Diagnostics Inc. TCKUCULVVY39
-
Mdxhealth, Inc.
Parent
LQGYDJJ9K8Q6
- SAM.gov registration date
- Physical address
- 266 2nd Ave #200, Waltham, MA 02451, USA
- Website
- mdxhealth.com
- Founded
- 2004
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| VISN 19 non-invasive prostate testing | Veterans Integrated Service Network 19 | $255,243 | |
| Exodx prostate intelliscore testing | Veterans Integrated Service Network 1 | $6,613 | |
| Exodxprostate testing | Veterans Integrated Service Network 7 | $87,176 | |
| Exodx prostate intelliscore testing | Veterans Integrated Service Network 1 | $270,000 | |
| Exodx prostate intelliscore testing | Veterans Integrated Service Network 1 | -$166,290 |
About Exosome Diagnostics Inc.
Exosome Diagnostics Inc., a subsidiary of Mdxhealth Inc. based in Waltham, Massachusetts, develops and delivers non-invasive liquid biopsy diagnostic tests to the Department of Veterans Affairs as a prime contractor under the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), with no set-aside designations across its federal portfolio. The company operates exclusively as a prime on federal contracts (80% of recent awards) and holds a single-award Blanket Purchase Agreement with VA VISN 1 valued at $1.352 million through December 2028.
Exosome Diagnostics' capability centers on ExoDx Prostate IntelliScore, a urine-based liquid biopsy test that analyzes exosomal RNA biomarkers to assess clinically significant prostate cancer risk in veterans. The test serves as a non-invasive alternative to digital rectal examination and operates under sole-source procurement authority based on the company's unique diagnostic capabilities in extracellular vesicle analysis. Representative prime contract work includes a $692,149.52 delivery order from VISN 6 (May 2022, performance through September 2026) for prostate screening at Richmond, Virginia; a $1.352 million BPA with VISN 1 (established December 2023, running five years) structured to deliver approximately 360 tests annually at West Haven, Connecticut and Waltham; and a $447,905.92 delivery order from VISN 7 (April 2026, performance through March 2031) for testing at Augusta, Georgia. All VA contracts operate on firm fixed-price structures with no set-aside designations.
The VA accounts for the vast majority of Exosome Diagnostics' customer concentration. The top five customers by award count account for 85% of recent awards: VISN 1 leads with four awards worth $1.8 million in combined potential value, followed by VISN 6 (four awards, $694 thousand), the National Institutes of Health National Cancer Institute (four awards, dollar amount not disclosed in source), VISN 2 (three awards, $410 thousand), and VISN 7 (two awards, $887 thousand). The potential-value ranking diverges at the top: VISN 12 anchors a single award worth $2.3 million in combined potential value, indicating a smaller number of higher-value delivery orders against the base FSS-621-II schedule. Exosome Diagnostics places all 16 of its prime federal contract orders under the Medical Laboratory Testing and Analysis Services FSS-621-II parent vehicle, with combined potential value of $4.2 million across those task orders.
Activity has grown unevenly—two awards in 2022, two in 2023, six in 2024, two in 2025, and one in 2026—with one award ($692 thousand) reaching ultimate completion in the next twenty-four months, representing modest recompete exposure. In its sub-award role, Exosome Diagnostics performs extracellular vesicle analysis and assay development work as a collaborator with Massachusetts General Hospital on two National Cancer Institute grant sub-awards: a November 2023 grant focused on ovarian cancer detection through EV screening and sensor-chip development, and a June 2025 grant for optimization and validation of GLIscan, a blood-based multiplexed assay for brain tumor diagnostics targeting IDH1, EGFRvIII, and telomerase mutations. Combined potential value across all awards (prime and sub) stands at $6.1 million, with $1.7 million obligated (29% draw-down), reflecting the early-stage draw on multi-year VA delivery orders and active grant work. The company's narrowly focused federal footprint—prostate cancer screening for VA populations and advanced cancer biomarker research through NIH grants—positions it as a specialized diagnostics provider with deep VA customer relationships but limited customer diversification.
Contract vehicles
Quick answers
What is Exosome Diagnostics Inc.'s UEI?
Exosome Diagnostics Inc.'s Unique Entity ID (UEI) in SAM.gov is TCKUCULVVY39.
What is Exosome Diagnostics Inc.'s CAGE code?
Exosome Diagnostics Inc.'s CAGE code is 554U8.
What is Exosome Diagnostics Inc.'s primary NAICS code?
Exosome Diagnostics Inc.'s primary NAICS code is 621511 (Medical Laboratories).
Where is Exosome Diagnostics Inc. located?
Exosome Diagnostics Inc.'s physical address in SAM.gov is 266 2nd Ave #200, Waltham, MA 02451, USA.
Is Exosome Diagnostics Inc. registered in SAM.gov?
Yes. Exosome Diagnostics Inc.'s SAM.gov registration is active through August 26, 2027.
Who is Exosome Diagnostics Inc.'s parent company?
Exosome Diagnostics Inc. is part of Mdxhealth, Inc.
Which contract vehicles does Exosome Diagnostics Inc. hold?
Exosome Diagnostics Inc. holds a place on 1 federal contract vehicle: FSS-621-II.
What is Exosome Diagnostics Inc.'s most recent federal award?
Exosome Diagnostics Inc.'s most recent federal contract award is VISN 19 non-invasive prostate testing (36C25926N0479), from Veterans Integrated Service Network 19, on September 15, 2026.
On GovTribe
See Exosome Diagnostics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors